# GSK account plan

> GSK is a biopharma group selling specialty medicines, vaccines and general medicines, with 2025 turnover of £32.7bn and 66,800 people.

## At a glance

GSK describes itself as a focused biopharma company that discovers, develops and delivers specialty medicines, vaccines and general medicines, with R&D centred on respiratory, immunology and inflammation, oncology, HIV (through ViiV Healthcare) and infectious diseases. It employs 66,800 people across 70 countries and runs 33 manufacturing sites. 2025 turnover was £32.7bn (+7% CER) and Core operating profit £9.8bn (+11% CER, margin 29.9%), with Core EPS of 172.0p and free cash flow of £4.0bn. The US is its largest region at £16.9bn of 2025 sales.

## Business units

- **Specialty Medicines** (41% of 2025 turnover (£13.5bn)): Medicines for complex or rare chronic conditions: HIV (£7.7bn, led by Dovato and long-acting Cabenuva and Apretude through ViiV Healthcare, run by Deborah Waterhouse), RI&I (£3.8bn, Nucala, Benlysta and the new Exdensur) and Oncology (£2.0bn, +43%, Jemperli, Ojjaara, Blenrep). Sales grew 17% CER in 2025, and GSK expects the unit to exceed 50% of sales by 2031.
- **Vaccines** (28% of 2025 turnover (£9.2bn)): Shingrix (£3.6bn, a record year with ex-US at 66% of its sales), meningitis vaccines led by Bexsero, Arexvy for RSV and established vaccines. Sales grew 2% CER in 2025 as US demand for Shingrix and Arexvy declined, then rose 8% to £2,284m in Q2 2026.
- **General Medicines** (31% of 2025 turnover (£10.0bn)): Primary-care medicines supplied in more than 100 countries, mostly respiratory and infectious disease; Trelegy (£3.0bn) offsets generic erosion. Sales fell 1% CER in 2025 and 9% in Q2 2026 as US Medicare changes hit Trelegy; spend is being reallocated to launches.

## Strategic priorities

- **More than £40bn of sales by 2031**: GSK targets sales above £40bn by 2031, with 15 launch opportunities each with peak sales potential above £2bn, and Specialty Medicines above 50% of sales.
- **Maximising launches**: The CEO's 2026 focus starts with launch products such as Exdensur (twice-yearly severe asthma treatment) and Blenrep (multiple myeloma).
- **Accelerating the late-stage pipeline**: A review accelerated 7 late-stage products across 18 indications, and GSK now expects 20+ phase III starts in 2026 (previously 10), including oncology ADCs, efimosfermin in MASH and long-acting TSLP.
- **Longer-acting HIV medicines**: ViiV targets three-times-yearly Apretude for PrEP in H1 2027, three-times-yearly Cabenuva in 2028 and twice-yearly treatment by the end of the decade, to navigate the dolutegravir loss of exclusivity.
- **Targeted business development**: Deals with a clear pathway to value creation: RAPT Therapeutics, 35Pharma and Nuvalent in 2026, after 14 partnerships and acquisitions in 2025.
- **Technology and AI at scale**: The Chair asks the new CEO to adopt technology at scale; technology and AI are one of three R&D priorities and a source of savings in the Accelerate Growth programme.

## Latest results

In Q2 2026, sales were £8,409m (+5% CER) and H1 sales £16,038m (+5% CER). Core operating profit rose 7% to £2,800m with a 33.3% margin, and Core EPS rose 9% to 50.5p. Specialty Medicines grew 14% to £3,782m and Vaccines 8%, while General Medicines fell 9%. Total operating profit fell 75% to £481m on a £1,334m camlipixant impairment and £371m on Alector-related assets. Guidance for 2026 at CER was reaffirmed: turnover +3% to 5% and Core operating profit +7% to 9%, both in the upper half, and Core EPS +7% to 9% in the lower half.

## Investments and deals

- **Nuvalent acquisition**: Closed 15 July 2026 for an equity value of about $10.6bn, funded mainly by debt, adding zidesamtinib and neladalkib in lung cancer.
- **RAPT Therapeutics and 35Pharma**: RAPT (US$2.3bn, completed 3 March 2026) adds ozureprubart for food allergy; 35Pharma (US$1.0bn, completed 14 April 2026) adds HS235 for pulmonary hypertension.
- **Accelerate Growth programme**: Targets £1.9bn of annual savings by 2029 for £2.4bn of costs, through technology and AI, support services, procurement and a simpler supply chain and site network; savings are mainly reinvested in R&D and business development.
- **Manufacturing and R&D sites**: $1.2bn over five years in US advanced manufacturing, AI and digital, including a biologics flex factory at Upper Merion, Pennsylvania; a new flagship R&D centre is planned on the Cambridge Biomedical Campus, UK.

## Challenges and risks

- **US pricing and policy**: US policy on international reference pricing, tariffs and the IRA Medicare Part D redesign weigh on sales; the April 2026 agreement gives Section 232 tariff relief through 20 January 2029.
- **Dolutegravir loss of exclusivity**: Dolutegravir loses exclusivity during 2028-2030, starting April 2028 in the US, with most of the impact in 2029-2030.
- **Weaker US vaccine demand**: US demand for Shingrix and Arexvy declined in 2025, with Shingrix US sales down 17%, amid vaccine hesitancy and competition.
- **Pipeline setbacks**: The CALM-1 and CALM-2 trials of camlipixant showed limited efficacy, leading to a £1,334m impairment in Q2 2026.
- **Cyber and supply continuity**: The annual report rates information and cyber security and supply continuity among principal risks increasing externally.

## What leadership says

> "Accelerating R&D is our biggest opportunity to create value as a company." — Luke Miels, Chief Executive Officer, GSK Annual Report 2025, March 2026

> "Products are the key in this business, and we need to be more product-centric." — Luke Miels, Chief Executive Officer, FY and Q4 2025 results call, 4 February 2026

> "We remain focused on operational delivery, execution, and accelerating R&D." — Luke Miels, Chief Executive Officer, Q2 2026 results announcement, 28 July 2026

> "has underperformed for many years and this marks only the start of a long-awaited recovery." — Sir Jonathan Symonds, Chair, Chair's statement on the share price, GSK Annual Report 2025


## Where a supplier can help

- **Clinical trial capacity**: Tied to the pipeline acceleration: going from 10 to 20+ phase III starts in 2026 creates demand for CROs, site networks and trial technology.
- **Launch commercialisation support**: Tied to the Exdensur and Blenrep launches: patient access, field-force and HCP engagement services for launches GSK calls its first focus area.
- **AI, procurement and support-service efficiency**: Tied to the Accelerate Growth programme: savings are to come from technology and AI, streamlining support services and procurement.
- **Manufacturing and site network**: Tied to the US manufacturing investment and supply-chain simplification: equipment, automation and digital tools for new and consolidated sites.
- **Integration of acquired biotechs**: Tied to the Nuvalent, RAPT and 35Pharma acquisitions: systems, data and regulatory integration of newly acquired programmes.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [GSK Annual Report 2025](https://www.gsk.com/media/kn0bknmd/annual-report-2025.pdf)

Annual report · 2026-03-04

- GSK is a focused biopharma group (66,800 people, 70 countries, 33 manufacturing sites) selling Specialty Medicines, Vaccines and General Medicines, with R&D centred on RI&I, oncology, HIV (via ViiV Healthcare) and infectious diseases.
- 2025 turnover £32.7bn (+7% CER); Core operating profit £9.8bn (+11% CER, margin 29.9%); Core EPS 172.0p (+12%); free cash flow £4.0bn; dividend 66p.
- Specialty Medicines is the growth engine: £13.5bn (41% of sales, +17% CER), with HIV £7.7bn, RI&I £3.8bn and Oncology £2.0bn (+43%); expected to exceed 50% of sales by 2031.
- Vaccines £9.2bn (+2% CER): Shingrix £3.6bn record year, ex-US now 66% of its sales; US demand for Shingrix and Arexvy declined. General Medicines £10.0bn (-1% CER), Trelegy £3.0bn offsetting generic erosion.
- Five major FDA approvals in 2025 (Exdensur, Blenrep, Nucala in COPD, Blujepa, Penmenvy); 58 pipeline assets, 15 launch opportunities by 2031 each with peak sales potential above £2bn.
- Targets: sales above £40bn by 2031; 2026 guidance of turnover +3-5%, Core operating profit and Core EPS +7-9% at CER; 2026 dividend expected at 70p.
- Leadership change: Luke Miels replaced Emma Walmsley as CEO at end-2025 and expanded the team into a new Executive Committee with US, Europe and International presidents and a Global Product Strategy head.
- Investing in US manufacturing ($1.2bn over five years) and AI, and in targeted business development (IDRx, efimosfermin, Hengrui, RAPT Therapeutics).
- Key risks: US drug pricing (December 2025 agreement with the US Administration, tariffs), IRA Medicare Part D, dolutegravir loss of exclusivity in 2028-2030, cyber and supply continuity.

### [GSK Second quarter 2026 results announcement](https://www.gsk.com/media/jayh41pz/q2-2026-results-announcement.pdf)

Interim report · 2026-07-28

- Q2 2026 sales £8.4bn (+5% CER); H1 sales £16,038m (+5% CER). Core operating profit £2.8bn (+7%), Core EPS 50.5p (+9%); Core operating margin 33.3%.
- Total operating profit fell 75% to £481m on a £1.3bn camlipixant impairment after the CALM-1/2 phase III trials, plus £371m on Alector-related assets and higher CCL charges.
- Specialty Medicines £3.8bn (+14%): HIV £2.1bn (+10%), RI&I £1.1bn (+19%), Oncology £0.6bn (+17%). Vaccines £2.3bn (+8%) with Arexvy and meningitis up; General Medicines £2.3bn (-9%), Trelegy -7% on US Medicare changes.
- New "Accelerate Growth" programme: £1.9bn annual savings by 2029 for £2.4bn of costs, savings mainly reinvested in R&D and business development; 7 late-stage assets accelerated across 18 indications; 20+ phase III starts expected in 2026 (previously 10).
- Acquired Nuvalent for about $10.6bn (closed 15 July 2026), adding zidesamtinib/Jideytro (FDA approved) and neladalkib in lung cancer; also RAPT ($2.3bn) and 35Pharma ($1.0bn) closed in H1.
- 2026 guidance reaffirmed: turnover +3-5% and Core operating profit +7-9% (both upper half), Core EPS +7-9% (lower half); 2031 sales outlook of more than £40bn reaffirmed.
- New flagship R&D centre planned on the Cambridge Biomedical Campus, UK. Q2 dividend 17p; £2bn buyback completed; net debt £15.1bn at 30 June 2026.
- US: definitive agreement of 9 April 2026 gives Section 232 tariff relief through 20 January 2029; GSK and ViiV joined the CMS Generous Model.

### [FY & Q4 2025 results: conference call and webcast transcript](https://www.gsk.com/media/ikagellq/fy-2025-results-transcript.pdf)

Executive talk · Luke Miels, Chief Executive Officer · 2026-02-04

- Luke Miels' first results call as CEO (4 February 2026): 2025 sales up 7% to more than £32bn, Specialty Medicines up 17%, Core operating profit +11%, EPS +12%, dividend raised 2p to 66p.
- Three 2026 focus areas: maximise launches (Blenrep, Exdensur), accelerate late-stage assets (B7-H3, B7-H4, velzatinib, efimosfermin, long-acting TSLP, six-monthly HIV regimen), and business development such as the RAPT/ozureprubart deal.
- Two value levers: topline (2031 ambition and the dolutegravir loss of exclusivity) and pipeline; GSK must be "more product-centric" with "more scientific courage".
- Commercial reshuffle: all Nucala reps moved to Exdensur; Nucala COPD promoted by the Trelegy team; Nucala has 43% to 46% of new COPD patient starts.
- HIV (Deborah Waterhouse): +11% in 2025, over 75% of growth from long-acting injectables; CUATRO four-monthly treatment to file in 2027 and launch in 2028; six-monthly treatment launch targeted 2028-2030.
- 2026 guidance (Julie Brown): sales +3-5%, Core operating profit and EPS +7-9%, dividend 70p; cash generated from operations on track for more than £10bn in 2026; profit growth weighted to H2.
- Miels on resources: GSK will "rapidly move resources, people, head count, capital" to the best opportunities, and reiterated the £40bn 2031 sales commitment.

### [Q1 2026 results: conference call and webcast transcript](https://www.gsk.com/media/sd2fi14q/q1-2026-results-transcript.pdf)

Executive talk · Luke Miels, Chief Executive Officer · 2026-04-29

- Q1 2026 call (29 April 2026): sales up 5% to more than £7.6bn, Specialty Medicines +14%, Core operating profit +10%, EPS +9%; Q1 dividend 17p; 2026 guidance confirmed.
- Shingrix set a quarterly record above £1bn (+20%), with Europe +51%; Jemperli £232m (+40%); Nucala has around 45% of the US COPD market share; Exdensur access limited until its J-code, expected early July.
- HIV +10% with US +15%; Cabenuva +31%, Apretude +44%; three-times-yearly Apretude for PrEP targeted for H1 2027 launch and three-times-yearly Cabenuva for 2028.
- Pipeline: bepirovirsen (hepatitis B) has a US PDUFA date of 26 October and Priority Review in China; mo-rez (B7-H4 ADC) moving into five pivotal trials; 10 phase III starts planned in 2026.
- Business development: RAPT (ozureprubart, food allergy) and 35Pharma (HS235, pulmonary hypertension) acquired; Rockville site and linerixibat divested.
- Miels describes a fortnightly portfolio review with the CEO and R&D/commercial heads, "a Darwinian process" to move resources to winning programmes and accelerate the late-stage pipeline.
- Net debt at 1.4x EBITDA; CFO targets more than £10bn cash generated from operations; operating profit growth weighted to H2.

## Questions about GSK

### What does GSK do?

GSK discovers, develops and sells specialty medicines, vaccines and general medicines, focusing on respiratory, immunology and inflammation, oncology, HIV and infectious diseases.

### What is GSK's revenue?

2025 turnover was £32.7bn (+7% CER) with Core operating profit of £9.8bn. H1 2026 sales were £16,038m (+5% CER).

### How many employees does GSK have?

GSK has 66,800 people across 70 countries and 33 manufacturing sites, according to its 2025 Annual Report.

### Who leads GSK?

Luke Miels succeeded Emma Walmsley as CEO at the end of 2025. Sir Jonathan Symonds is Chair and Julie Brown is CFO.

### What is GSK's strategy?

GSK aims for sales above £40bn by 2031 by maximising launches, accelerating its late-stage pipeline, extending long-acting HIV medicines and adding assets through targeted business development.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
